ResMed: 800 million undiagnosed sleep apnea patients, one dominant device maker trading at a discount to its own earnings trajectory

Stevie AI on ResMed Inc. (RMD-USA | resmedincrmd)

6/1/2026

Summary

ResMed is the global leader in sleep apnea therapy, holding dominant positions across CPAP devices, mask resupply, and cloud-connected digital health across 140 countries. The structural thesis rests on a deceptively simple arithmetic: roughly 80% of the estimated one billion people with obstructive sleep apnea remain undiagnosed and untreated, and ResMed is the best-positioned company to convert that latent demand into recurring, high-margin revenue. Unlike most medical device businesses, ResMed benefits from a consumable resupply engine — masks and accessories replaced every three to six months — that layers durable annuity cash flows on top of device unit growth. The feared GLP-1 disruption narrative, which compressed the share price sharply in late 2023, has empirically failed to materialize: real-world adherence data shows GLP-1 patients continuing and in many cases increasing PAP therapy use, because pharmacological weight loss improves therapy tolerance rather than eliminating therapy need. The market has partially re-rated the stock but has not yet fully priced the earnings trajectory now visible through FY2028. ResMed delivered $4.2 billion in revenue in FY2023 and $4.7 billion in FY2024, with net income growing from $0.9 billion to $1.0 billion and EPS advancing from $6.09 to $6.92. Gross margin has already expanded to approximately 62.8%, demonstrating the pricing power and supply chain discipline that management has executed following the post-COVID component cost cycle. Operating leverage is pronounced: revenue grew roughly 12% year-over-year in FY2024, yet operating margins continued expanding as the fixed-cost base of the digital platform is increasingly amortized across a growing installed base. The balance sheet has been actively deleveraged following the FY2023 acquisition cycle, and free cash flow conversion remains above 90% of net income — a quality metric that separates ResMed from capital-intensive device peers. Applying a 26x forward P/E multiple — justified by ResMed's combination of 12-14% annual EPS growth, 62%+ gross margins, greater than 90% FCF conversion, and a recurring consumables revenue mix that warrants a premium to the broader medical device sector median of roughly 22-23x — we derive price targets of $188 in FY2025, $234 in FY2026, $275 in FY2027, and $320 in FY2028. At the current price of $190.57, the stock trades essentially at our FY2025 target, implying the market is pricing zero earnings growth beyond the current fiscal year. The FY2026 target alone represents approximately 23% upside, with the FY2028 target implying 68% total return from current levels. The investment case is not predicated on multiple expansion — it is predicated on the market eventually crediting an earnings stream that the business is already generating.

Thesis

1. **The GLP-1 Overhang Was a Misread, and the Reversal Is Still Incomplete** The single largest re-rating event for ResMed in recent years was the market's initial fear that GLP-1 agonists — semaglutide, tirzepatide and successors — would structurally reduce the addressable market for CPAP therapy by inducing sufficient weight loss to resolve OSA in a meaningful patient cohort. At its most acute, this concern shaved roughly 30-35% from ResMed's equity value in 2023, a drawdown disproportionate to any sober reading of the clinical literature. The flaw in the bear thesis was a category error: it conflated OSA incidence with OSA severity, and assumed that weight loss alone would eliminate therapy need at scale. Real-world data has since clarified the picture. OSA is a multifactorial condition with anatomical, neuromuscular, and positional determinants that persist independent of adiposity in a large proportion of patients. More importantly, GLP-1-driven weight loss appears to improve CPAP tolerance and adherence — reducing the airway resistance and pharyngeal collapsibility that makes therapy uncomfortable — meaning the GLP-1 cohort may represent an incremental adherent patient population rather than a substitution. ResMed's own real-world analyses support sustained or improving PAP adherence rates among GLP-1 co-therapy patients. The bear case required GLP-1 to be a near-perfect substitute for CPAP; the clinical reality is that it is more accurately a complement. The stock has partially recovered but consensus estimates and forward multiples still embed residual GLP-1 discount. At 26x forward earnings, ResMed trades below the multiple it commanded before the GLP-1 narrative emerged, despite a stronger balance sheet, higher margins, and a more diversified revenue mix than it possessed in 2021-2022. The de-rating has not been fully reversed, and that gap is the opportunity. 2. **Consumables Create a Revenue Quality Premium the Multiples Don't Fully Reflect** ResMed's revenue architecture is structurally superior to a pure capital equipment business, and that superiority is underappreciated in a sector context where most medical device companies derive the majority of revenue from one-time device sales. Masks, cushions, and accessories are replaced on a three-to-six-month resupply cycle under insurance-reimbursed DME programmes in the United States and equivalent reimbursement structures in most developed markets. This means every CPAP device placed into a patient's home initiates a recurring revenue stream that compounds for the lifetime of therapy — typically measured in decades. The installed base of active ResMed device users numbers in the tens of millions globally, and that base grows every quarter as new patients are initiated and existing patients maintain therapy. Mask and accessories revenue therefore has meaningful revenue visibility — it is not subject to hospital capital budget cycles, elective procedure deferrals, or the lumpy ordering patterns that characterise surgical device businesses. This recurring layer partially insulates ResMed from the unit cycle volatility that affected competitors during and after the Philips recall, and it provides a margin floor during periods of slower device growth. The resupply dynamic also creates switching costs at the patient level that are systematically undervalued. Patients who are adherent to a specific mask interface — particularly the fabric-cushion AirTouch M20 variants that have driven a six-percentage-point adherence improvement in published data — are highly unlikely to accept substitution to an alternative brand's interface mid-therapy. That behavioural stickiness translates into durable market share at the SKU level that competitive pricing alone cannot easily dislodge. 3. **Gross Margin Expansion Toward 62-63% Is Structural, Not Cyclical** ResMed's gross margin trajectory is one of the clearest signals of business quality improvement in the current forecast period. Having already reached approximately 62.8% in recent quarters, management has guided explicitly to a 62-63% range for full FY2026, with continued double-digit basis point annual improvement committed through 2030. This is not a recovery to a prior peak — it represents a step-change in the margin structure enabled by platform standardisation, supply chain rationalisation, and the fixed-cost leverage of the digital platform. The key drivers are identifiable and execution-dependent rather than macro-dependent. Platform standardisation across the AirSense and AirCurve device families reduces component variety and enables procurement scale. Vendor management initiatives are compressing component costs per unit as volumes increase. Manufacturing cycle time improvements reduce work-in-process inventory and lower per-unit overhead absorption. Logistics optimisation, particularly in the Asia-Pacific supply chain, is reducing freight and warehousing costs that were elevated through the COVID cycle. None of these are speculative — they are multi-year programmes with measurable progress already visible in the gross margin line. Operating leverage compounds the gross margin story. ResMed's digital infrastructure — myAir patient engagement, AirView provider platform, VirtualOx remote monitoring — has substantial fixed costs that do not scale linearly with revenue. As the connected device installed base expands, the incremental cost of onboarding additional patients onto the platform is negligible. This means that 12-13% revenue growth translates into significantly faster operating income growth, which is precisely the trajectory visible in the forecast: net income growing from $1.0 billion in FY2024 to $2.2 billion in FY2028, a compound rate approximately four to five percentage points above revenue growth. 4. **Free Cash Flow Acceleration Enables a Capital Return Narrative That Hasn't Fully Priced In** FCF of $1.5 billion in FY2025 rising to $2.1 billion by FY2028 against a current market capitalisation of approximately $28 billion implies a FY2028 FCF yield of approximately 7.5% at the current price. For a business with this margin profile, growth trajectory, and balance sheet quality, a 7.5% FCF yield represents a material mispricing relative to the risk-adjusted returns available elsewhere in healthcare technology. The FCF yield compression alone — as the market re-rates toward a 4-5% FCF yield more consistent with the business's quality — would drive substantial price appreciation independent of earnings multiple expansion. The balance sheet context matters here. ResMed entered a net cash position of approximately $0.1 billion in FY2025, transitioning from the net debt position accumulated through the FY2023 acquisition cycle. By FY2027, net cash reaches $1.9 billion; by FY2028, $3.0 billion. This rapid accumulation creates optionality across three capital allocation levers: accelerating share buybacks (which mechanically support EPS growth beyond net income growth), growing the dividend (currently modest but with substantial coverage headroom), and strategic tuck-in acquisitions in adjacent digital health or sleep diagnostic categories. The Noctrix Health acquisition, expected to close June 1, 2026, is an early signal of how ResMed intends to deploy that capital. Noctrix's neuromuscular electrical stimulation approach to restless legs syndrome represents a logical adjacency — a sleep-adjacent condition with a large undiagnosed patient pool, recurring therapy need, and a reimbursement pathway through the same DME channel infrastructure that ResMed already dominates. The Q4 FY2026 earnings call will be the first opportunity for new CFO Aaron Blumer to articulate a formal capital allocation framework, and any positive signal on buyback acceleration or RCS rationalisation proceeds could be an incremental catalyst. 5. **140-Country Penetration Story Provides a Long Duration Growth Runway** The United States is the most developed sleep apnea market in the world, with relatively high diagnosis rates, established DME reimbursement infrastructure, and physician awareness of OSA co-morbidities. Yet even in the US, the majority of OSA sufferers remain undiagnosed. Outside the US, the gap is far wider — in most of Asia-Pacific, Latin America, and emerging EMEA markets, diagnosis rates are estimated below 10% of the affected population. ResMed operates in all 140 countries with meaningful commercial infrastructure, meaning the addressable market expansion is not a theoretical future opportunity but an active commercial programme already generating growth. International revenue has been a consistent growth driver and is becoming a larger proportion of the total as US market penetration matures relative to the global opportunity. The digital connectivity of ResMed's platform creates a network effect in international markets: as HME providers and sleep clinics in new markets adopt AirView for remote monitoring and titration management, switching costs increase at the provider level and competitive displacement becomes progressively harder. The platform also enables ResMed to serve markets where in-person follow-up care is limited — remote CPAP management is not merely a convenience feature in developed markets but a functional necessity in markets with sparse specialist infrastructure. Revenue growth forecasts of 10-13% annually through FY2028 are therefore credible without requiring any assumption of heroic market share gains in existing geographies. The combination of existing market penetration depth improvement, new patient identification (including GLP-1 co-identified OSA patients), and international geographic expansion provides three independent growth vectors, any two of which would be sufficient to sustain the forecast trajectory. 6. **Residential Care Software Rationalisation Is an Overlooked Earnings Quality Catalyst** ResMed's Residential Care Software segment — legacy senior living and long-term care management software acquired through the Brightree and MatrixCare transactions — has been a persistent source of investor concern around strategic coherence. The segment generates revenue and contributes to operating income, but it sits awkwardly alongside a sleep-focused digital health narrative and has attracted periodic speculation about divestiture. Management has confirmed a portfolio rationalisation process is underway. A partial or full divestiture of RCS assets would be a meaningful catalyst on multiple dimensions. Proceeds would accelerate the net cash build already visible in the forecast, providing incremental buyback capacity. More importantly, removing the segment would simplify the ResMed investment thesis, improve reported operating margins on the remaining core business (which carries higher margins than the software segment), and potentially re-rate the multiple as the company becomes a purer-play sleep and respiratory health platform. The timing of CFO Blumer's capital allocation commentary in Q4 FY2026 will be the first formal window into how aggressively management pursues this path. Even absent a full divestiture, margin improvement within RCS through product rationalisation and cost reduction contributes to the consolidated operating margin expansion embedded in the FY2027-28 forecast.

Risks

1. **GLP-1 Thesis Execution Risk: Clinical Outcomes Could Diverge From Real-World Adherence Data** The single most material risk to the investment thesis is that ResMed's real-world adherence analyses, which currently show GLP-1 co-therapy patients maintaining or improving PAP use, prove to be a transitional observation rather than a durable steady-state. If longer-duration GLP-1 use — particularly at the higher doses and extended treatment periods now entering clinical practice — produces weight loss sufficient to resolve OSA anatomically in a meaningful cohort, therapy discontinuation rates could rise materially. The risk is compounded by the possibility that next-generation GLP-1 compounds with superior efficacy profiles accelerate this dynamic faster than current data would suggest. ResMed's revenue model is highly sensitive to adherence rates: a sustained decline in average therapy duration per patient would compress both device replacement and mask resupply revenue simultaneously, with limited near-term offset available from new patient initiations. 2. **Philips Recall Tailwind Reversal: Market Share Normalisation as Philips Re-enters the Market** ResMed's strong device revenue growth in FY2023 and FY2024 was materially assisted by Philips' recall of its DreamStation CPAP platform, which removed the primary global competitor from the market for an extended period and forced patients and providers to adopt ResMed equipment. As Philips completes its remediation programme and reintroduces devices, the competitive intensity in the device segment will increase. The degree to which ResMed retains the patients and DME channel relationships acquired during the Philips disruption period is uncertain. If Philips offers aggressive pricing or promotional terms to recapture market share, ResMed may face device ASP pressure or volume deceleration. The forecast's 10-13% revenue growth assumption implicitly assumes Philips re-entry is manageable and partially offset by international growth — any sharper-than-expected domestic volume normalisation would compress near-term revenue and operating leverage. 3. **Tariff and Geopolitical Supply Chain Disruption** ResMed manufactures across a globally distributed supply chain with significant exposure to Asia-Pacific component sourcing and manufacturing. The current geopolitical environment — including US-China trade tensions, potential tariff escalation, and supply chain localisation pressures — creates cost and operational risk that management has acknowledged. Component cost inflation, logistics disruption, or forced supply chain restructuring could compress gross margins below the 62-63% guided range, delaying or reversing the margin expansion central to the earnings trajectory forecast. The gross margin guide to 62-63% for FY2026 was issued with an explicit caveat around near-term component cost inflation pressures, and any geopolitical deterioration affecting semiconductor, precision component, or electronics supply chains would directly impact ResMed's cost structure. 4. **DME Reimbursement and Competitive Bidding Pressure in the US** Approximately half of ResMed's revenue flows through the US home medical equipment channel, where reimbursement rates for CPAP devices and supplies are set through CMS competitive bidding rounds. Adverse outcomes in future competitive bidding cycles — including rate reductions, category reclassifications, or stricter prior authorisation requirements — would directly reduce the economics of DME channel partners and place pressure on ResMed device and accessory pricing. There is also ongoing regulatory scrutiny around DME billing practices and resupply programme compliance, and any enforcement action against major HME customers could disrupt the resupply revenue stream that underpins the recurring cash flow model. This risk is partially structural and cannot be fully hedged through international diversification in the near term. 5. **Noctrix Integration and RLS Market Sizing Uncertainty** The Noctrix Health acquisition, while strategically logical as a sleep-adjacent expansion, introduces integration execution risk in a therapeutic category where ResMed has no prior commercial experience. Restless legs syndrome affects an estimated 5-15% of the adult population, but commercially actionable diagnosis rates, reimbursement pathways, and prescriber behaviour in this category are materially less developed than in OSA. If Noctrix's neuromuscular stimulation technology fails to achieve adequate reimbursement coverage at scale, or if the RLS market proves more fragmented and specialist-dependent than ResMed's DME channel model is suited to address, the acquisition could prove a distraction to capital and management attention without generating meaningful revenue contribution. Q4 FY2026 will be the first financial disclosure, and any negative signal on reimbursement access or commercial ramp could weigh on sentiment disproportionately given current expectations. 6. **Residential Care Software Divestiture Execution Risk** While RCS rationalisation is presented in the thesis as a positive catalyst, the execution risk runs in both directions. A failed or delayed divestiture process — whether due to lack of qualified buyers at acceptable valuations, regulatory complications, or contractual encumbrances in the software customer base — would leave ResMed managing a structurally lower-margin, slower-growth segment indefinitely. Alternatively, a divestiture conducted under adverse market conditions for software assets could generate proceeds below book value, creating a one-time earnings headwind. There is also transition risk: RCS generates meaningful operating income contribution, and any revenue or customer attrition during a transition period could temporarily weaken consolidated financials at a time when the core device business is expected to sustain strong growth. The rationalisation timeline remains undefined, and extended uncertainty around the segment's future could suppress the multiple re-rating that a clean divestiture would otherwise catalyse.

📈 Price Targets